Trials / Completed
CompletedNCT05777616
The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 166 (actual)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 14 Years
- Healthy volunteers
- Not accepted
Summary
The IFX adherence to CD in China was not high. Medicine concerns may be predictive factor of adherence. By enhancing knowledge and relieving medicine concerns, we may increase patients' adherence to IFX.
Detailed description
Crohn's disease (CD) is an incurable chronic disease that requires long-term treatment. As an anti-tumor necrosis factor (TNF) agent, Infliximab (IFX) is widely used in the treatment of Crohn's disease, while the adherence is not high. The purpose of this study was to investigate the adherence to IFX among CD patients in China and evaluate the association between medication belief and IFX adherence.
Conditions
Timeline
- Start date
- 2021-11-15
- Primary completion
- 2021-12-28
- Completion
- 2021-12-28
- First posted
- 2023-03-21
- Last updated
- 2023-03-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05777616. Inclusion in this directory is not an endorsement.